Listed

U S Physical Therapy Inc: Form 10-Q for the period ended Sep 30, 2014

Filed with the SEC on Nov 7, 2014 and accepted by EDGAR at Nov 7, 2014, 10:51 ET.

Share

Management's discussion and analysis

As filed, 27,631 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following is a discussion of our historical consolidated financial condition and results of operations, and should be read in conjunction with (i) our historical consolidated financial statements and accompanying notes thereto included elsewhere in this Quarterly Report on Form 10-Q; (ii) our Annual Report on Form 10-K for the year ended December 31, 2013 filed with the Securities and Exchange Commission (the “SEC”) on March 11, 2014; and (iii) our management’s discussion and analysis of financial condition and results of operations included in our 2013 Form 10-K. This discussion includes forward-looking statements that are subject to risk and uncertainties. This discussion includes forward-looking statements that are subject to risk and uncertainties. Actual results may differ substantially from the statements we make in this section due to a number of factors that are discussed in “Forward-Looking Statements” herein and “Part I – Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2013

References to “we,” “us,” “our” and the “Company” shall mean U.S. Physical Therapy, Inc. and its subsidiaries.

EXECUTIVE SUMMARY

Our Business

We operate outpatient physical therapy clinics that provide preventive and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. As of September 30, 2014, we operated 489 clinics in 42 states.

We also manage physical therapy facilities for third parties, primarily physicians, with 18 third-party facilities under management as of September 30, 2014.

On September 30, 2013, we sold the remainder of our physician services business. The results of operations and the loss on the sale of the physician services business have been reclassified to discontinued operations for all periods presented.

The following discussion refers to continuing operations unless otherwise noted.

During the first nine months of 2014 and the year ended 2013, we acquired the following clinic groups:

Acquisition Date Acquired Clinics Date
April 2014 Acquisition April 30 70% 13 April 30, 2014
August 2014 Acquisition August 1 100% 3 August 1, 2014
February 2013 Acquisition February 28 72% 9 February 28, 2013
April 2013 Acquisition April 30 50% 5 April 30, 2013
May 2013 Acquisition May 24 80% 5 May 24, 2013
December 9, 2013 Acquisition December 9 60% 12 December 9, 2013
December 13, 2013 Acquisition December 13 90% 11 December 13, 2013

The Company purchased interests in two partnerships which were previously classified as redeemable non-controlling interest on August 1, 2014. The interests in the partnerships purchased ranged from 10.0% to 35.0%. In addition to the above clinic group acquisitions, in 2014, we acquired three individual clinic practices in separate transactions. Two of the acquired clinics will operate as satellites of two of our partnerships and the other will be consolidated into an existing clinic. Also, in 2013, we acquired three physical therapy clinic practices in separate transactions.

The results of operations of the acquired clinics have been included in our consolidated financial statements since the date of their acquisition.

Selected Operating and Financial Data

The following table presents selected operating and financial data that we believe are key indicators of our operating performance.

For the Three Months Ended September 30, , 2014 2013 For the Nine Months Ended September 30, 2014 2013
Number of clinics, at the end of period 489 447 489 447
Working days 64 64 191 191
Average visits per day per clinic 23.0 21.3 22.6 21.3
Total patient visits 719,271 611,448 2,081,907 1,802,870
Net patient revenue per visit $105.92 $105.27 106.18 $105.96

RESULTS OF OPERATIONS

Three Months Ended September 30, 2014 Compared to the Three Months Ended September 30, 2013

  • Net revenues increased to $77.7 million for the three months ended September 30, 2014 (“2014 Third Quarter”) from $65.8 million for the three months ended September 30, 2013 (“2013 Third Quarter”) primarily due to an increase in visits of 107,800 from 611,500 for the 2013 Third Quarter to 719,300 for the 2014 Third Quarter and a slight increase in the average net patient revenue per visit for the 2014 Third Quarter to $105.92 from $105.27 in the 2013 Third Quarter.
  • Net income attributable to our common shareholders for the 2014 Third Quarter was $5.2 million versus $4.7 million for the 2013 Third Quarter. Net income was $0.43 per diluted share for the 2014 period and $0.38 for the 2013 period. Total diluted shares were 12.2 million for the 2014 Third Quarter and 12.1 million for the 2013 Third Quarter.

Net Patient Revenues

  • Net patient revenues increased to $76.2 million for the 2014 Third Quarter from $64.3 million for the 2013 Third Quarter, an increase of $11.9 million, or 18.4%, due to visits of 80,600 from clinics opened and acquired between October 1, 2013 and September 30, 2014 (“New Clinics”) and an increase in visits of 27,200 from clinics opened or acquired prior to October 1, 2013 (“Mature Clinics”) and an increase in the net patient revenue per visit of $0.65.
  • Net patient revenues related to New Clinics amounted to $9.6 million for the 2014 Third Quarter and net patient revenues for Mature Clinics increased by $2.3 million for the 2014 Third Quarter as compared to the 2013 Third Quarter.

Net patient revenues are based on established billing rates less allowances and discounts for patients covered by contractual programs and workers’ compensation. Net patient revenues are determined after contractual and other adjustments relating to patient discounts from certain payors. Payments received under these programs are based on predetermined rates and are generally less than the established billing rates.

Other Revenues

Other revenues increased slightly in the 2014 Third Quarter compared to the 2013 Third Quarter.

Clinic Operating Costs

Clinic operating costs were $59.0 million, or 75.9% of net revenues, for the 2014 Third Quarter and $49.7 million, or 75.5% of net revenues, for the 2013 Third Quarter. The increase was primarily attributable to $8.1 million in operating costs of New Clinics and by an increase in operating costs of $1.2 million for Mature Clinics. Each component of clinic operating costs is discussed below:

Clinic Operating Costs—Salaries and Related Costs

Salaries and related costs increased to $41.8 million for the 2014 Third Quarter from $35.7 million for the 2013 Third Quarter, an increase of $6.1 million, or 17.0%. Salaries and related costs for New Clinics amounted to $5.6 million for the 2014 Third Quarter. Salaries and related costs for Mature Clinics increased by $0.5 million for the 2014 Third Quarter as compared to the 2013 Third Quarter. Salaries and related costs as a percentage of net revenues were 53.8% for the 2014 Third Quarter and 54.3 % for the 2013 Third Quarter.

Clinic Operating Costs—Rent, Clinic Supplies, Contract Labor and Other

Rent, clinic supplies, contract labor and other were $16.1 million for the 2014 Third Quarter and $12.9 million for the 2013 Third Quarter. For New Clinics, rent, clinic supplies, contract labor and other amounted to $2.5 million for the 2014 Third Quarter. For Mature Clinics, rent, clinic supplies, contract labor and other increased by $0.7 million in the 2014 Third Quarter compared to the 2013 Third Quarter. Rent, clinic supplies, contract labor and other as a percentage of net revenues was 20.7% for the 2014 Third Quarter and 19.6% for the 2013 Third Quarter.

Clinic Operating Costs—Provision for Doubtful Accounts

The provision for doubtful accounts was $1.1 million for the 2014 Third Quarter and $1.1 million for the 2013 Third Quarter. The provision for doubtful accounts for patient accounts receivable as a percentage of net patient revenues was 1.4% for the 2014 Third Quarter and 1.7% for the 2013 Third Quarter.

Our allowance for doubtful accounts for patient accounts receivable as a percentage of total patient accounts receivable was 5.1% at September 30, 2014, as compared to 4.4% at December 31, 2013. Our day’s sales outstanding were 41 days at September 30, 2014 and 39 days at December 31, 2013.

Corporate Office Costs

Corporate office costs, consisting primarily of salaries and benefits of corporate office personnel, rent, insurance costs, depreciation and amortization, travel, legal, accounting, professional, and recruiting fees, were $7.5 million for the 2014 Third Quarter and $6.2 million for the 2013 Third Quarter. The increase was primarily due to an increase in the number of employees and the amount of accrued incentive compensation. As a percentage of net revenues, corporate office costs were 9.6% for the 2014 Third Quarter and 9.5% for the 2013 Third Quarter.

Interest Expense

Interest expense increased to $0.2 million in the 2014 Third Quarter compared to $0.1 million in the 2013 Third Quarter due to a higher average outstanding balance under our revolving credit agreement during the 2014 period as compared to the 2013 period due to acquisitions. At September 30, 2014, $46.5 million was outstanding under our revolving credit agreement.

Provision for Income Taxes

The provision for income taxes was $3.6 million for the 2014 Third Quarter and $3.0 million for the 2013 Third Quarter. During the 2014 and 2013 Third Quarters, we accrued state and federal income taxes at an effective tax rate (provision for taxes divided by the difference between income before taxes and net income attributable to non-controlling interests) of 41.0% and 39.0%, respectively.

Non-controlling Interests

Net income attributable to non-controlling interests, inclusive of discontinued operations, was $2.2 million for the 2014 Third Quarter and $2.0 million for the 2013 Third Quarter. Net income attributable to non-controlling interests, exclusive of discontinued operations, was $2.2 million for the 2014 Third Quarter and $2.1 million for the 2013 Third Quarter or as a percentage of operating income before corporate office costs was 11.7% for the 2014 Third Quarter and 13.0% for the 2013 Third Quarter.

Nine Months Ended September 30, 2014 Compared to the Nine Months Ended September 30, 2013

  • Net revenues increased to $225.7 million for the nine months ended September 30, 2014 (“2014 First Nine Months”) from $195.5 million for the nine months ended September 30, 2013 (“2013 First Nine Months”) primarily due to an increase in visits of 279,000 from 1,802,900 for the 2013 First Nine Months to 2,081,900 for the 2014 First Nine Months.
  • Net income attributable to our common shareholders for the 2014 First Nine Months was $15.9 million versus $13.6 million for the 2013 First Nine Months. Net income was $1.30 per diluted share for the 2014 period and $1.12 for the 2013 period. Total diluted shares were 12.2 million for the 2014 First Nine Months and 12.1 million for the 2013 First Nine Months.

Net Patient Revenues

  • Net patient revenues increased to $221.1 million for the 2014 First Nine Months from $191.0 million for the 2013 First Nine Months, an increase of $30.1 million, or 15.7%, due to an increase in visits of 185,000 from New Clinics and an increase in visits of 94,000 from Mature Clinics. The average net revenue per visit for the current period was $106.18 and $105.96 for the comparable 2013 period.
  • Net patient revenues related to New Clinics amounted to $22.6 million for the 2014 First Nine Months and net patient revenues for Mature Clinics increased by $7.5 million for the 2014 First Nine Months as compared to the 2013 First Nine Months primarily due to the acquisitions that occurred in the 2013 First Nine Months.

Net patient revenues are based on established billing rates less allowances and discounts for patients covered by contractual programs and workers’ compensation. Net patient revenues are determined after contractual and other adjustments relating to patient discounts from certain payors. Payments received under these programs are based on predetermined rates and are generally less than the established billing rates.

Other Revenues

Other revenues increased by $0.2 million in the 2014 First Nine Months to $4.6 million from $4.4 million in the 2013 First Nine Months.

Clinic Operating Costs

Clinic operating costs as a percentage of net revenues were $168.5 million, or 74.6% of net revenues, for the 2014 First Nine Months and $146.9 million, or 75.2% of net revenues, for the 2013 First Nine Months. The increase was primarily attributable to $18.4 million in operating costs of New Clinics and an increase in operating costs of $3.2 million for Mature Clinics. Each component of clinic operating costs is discussed below:

Clinic Operating Costs—Salaries and Related Costs

Salaries and related costs increased to $119.9 million for the 2014 First Nine Months from $105.3 million for the 2013 First Nine Months, an increase of $14.6 million, or 13.8%. Salaries and related costs for New Clinics amounted to $12.4 million for the 2014 First Nine Months. Salaries and related costs for Mature Clinics increased by $2.2 million for the 2014 First Nine Months as compared to the 2013 First Nine Months. Salaries and related costs as a percentage of net revenues were 53.1% for the 2014 First Nine Months and 53.9% for the 2013 First Nine Months.

Clinic Operating Costs—Rent, Clinic Supplies, Contract Labor and Other

Rent, clinic supplies, contract labor and other were $45.5 million for the 2014 First Nine Months and $38.2 million for the 2013 First Nine Months. For New Clinics, rent, clinic supplies, contract labor and other amounted to $5.8 million for the 2014 First Nine Months. For Mature Clinics, rent, clinic supplies, contract labor and other increased by $1.5 million in the 2014 First Nine Months compared to the 2013 First Nine Months. Rent, clinic supplies, contract labor and other as a percentage of net revenues was 20.2% for the 2014 First Nine Months and 19.5% for the 2013 First Nine Months.

Clinic Operating Costs—Provision for Doubtful Accounts

The provision for doubtful accounts was $3.1 million for the 2014 First Nine Months and $3.4 million for the 2013 First Nine Months. The provision for doubtful accounts for patient accounts receivable as a percentage of net patient revenues was 1.4% for the 2014 First Nine Months and 1.8% for the 2013 First Nine Months.

Our allowance for doubtful accounts for patient accounts receivable as a percentage of total patient accounts receivable was 5.1% at September 30, 2014, as compared to 4.4% at December 31, 2013. Our days sales outstanding was 41 days at September 30, 2014 and 39 days at December 31, 2013.

Corporate Office Costs

Corporate office costs, consisting primarily of salaries and benefits of corporate office personnel, rent, insurance costs, depreciation and amortization, travel, legal, accounting, professional, and recruiting fees, were $22.2 million for the 2014 First Nine Months and $19.2 million for the 2013 First Nine Months. The increase was primarily due to increase in the number of employees and the amount of accrued incentive compensation. As a percentage of net revenues, corporate office costs were 9.8% for both the 2014 First Nine Months and 2013 First Nine Months.

Interest Expense

Interest expense increased to $0.8 million in the 2014 First Nine Months compared to $0.4 million in the 2013 First Nine Months due to a higher average outstanding balance under our revolving credit agreement during the 2014 period compared to the 2013 period due to acquisitions. At September 30, 2014, $46.5 million was outstanding under our revolving credit agreement.

Provision for Income Taxes

The provision for income taxes was $11.0 million for the 2014 First Nine Months and $8.9 million for the 2013 First Nine Months. During the 2014 and 2013 First Nine Months, we accrued state and federal income taxes at an effective tax rate (provision for taxes divided by the difference between income before taxes and net income attributable to non-controlling interests) of 41.0% and 38.9%, respectively.

Non-controlling Interests

Net income attributable to non-controlling interests, inclusive of discontinued operations, was $7.3 million for the 2014 First Nine Months and $6.4 million for the 2013 First Nine Months. Net income attributable to non-controlling interests, exclusive of discontinued operations, was $7.3 million for the 2014 First Nine Months and $6.6 million for the 2013 First Nine Months or as a percentage of operating income before corporate office costs was 11.7% for the 2014 First Nine Months and 13.6% for the 2013 First Nine Months.

LIQUIDITY AND CAPITAL RESOURCES

We believe that our business is generating sufficient cash flow from operations to allow us to meet our short-term and long-term cash requirements, other than those with respect to future acquisitions. At September 30, 2014 and December 31, 2013, we had $15.8 million and $12.9 million, respectively, in cash. Although the start-up costs associated with opening new clinics and our planned capital expenditures are significant, we believe that our cash and unused availability under our revolving credit agreement are sufficient to fund the working capital needs of our operating subsidiaries, corporate costs, dividends, purchases of our common stock, accrued clinic closure costs, future clinic development and investments through at least March 2015. The amount outstanding under our revolving credit facility was $46.5 million at September 30, 2014 compared to $40.0 million at December 31, 2013. At September 30, 2014, we had $78.5 million available under our revolving credit facility. Significant acquisitions would likely require financing under our revolving credit facility.

During the nine months ended September 30, 2014, $28.8 million was provided by operations and $6.5 million was drawn on our revolving credit agreement. The major uses of cash included: purchases of businesses ($12.2 million), distributions to non-controlling interest partners ($7.1 million), purchases of non-controlling interests ($5.0 million), payment of dividends to our shareholders ($4.4 million) and purchases of fixed assets ($3.9 million).

Effective December 5, 2013, we entered into an Amended and Restated Credit Agreement with a commitment for a $125.0 million revolving credit facility with a maturity date of November 30, 2018 (“Credit Agreement”). The Credit Agreement is unsecured and has loan covenants, including requirements that we comply with a consolidated fixed charge coverage ratio and consolidated leverage ratio. Proceeds from the Credit Agreement may be used for working capital, acquisitions, purchases of our common stock, dividend payments to our common shareholders, capital expenditures and other corporate purposes. The pricing grid is based on our consolidated leverage ratio with the applicable spread over LIBOR ranging from 1.5% to 2.5% or the applicable spread over the Base Rate ranging from 0.1% to 1%. Fees under the Credit Agreement include an unused commitment fee ranging from 0.1% to 0.25% depending on our consolidated leverage ratio and the amount of funds outstanding under the Credit Agreement. On September 30, 2014, $46.5 million was outstanding on the revolving credit facility resulting in $78.5 million of availability, and we were in compliance with all of the covenants thereunder.

Historically, we have generated sufficient cash from operations to fund our development activities and to cover operational needs. We plan to continue developing new clinics and making additional acquisitions. We also from time to time purchase the non-controlling interests in our Clinic Partnerships. Generally, any acquisition or purchase of non-controlling interests is expected to be accomplished using a combination of cash and financing. Any large acquisition would likely require financing.

We make reasonable and appropriate efforts to collect accounts receivable, including applicable deductible and co-payment amounts, in a consistent manner for all payor types. Claims are submitted to payors daily, weekly or monthly in accordance with our policy or payor’s requirements. When possible, we submit our claims electronically. The collection process is time consuming and typically involves the submission of claims to multiple payors whose payment of claims may be dependent upon the payment of another payor. Claims under litigation and vehicular incidents can take a year or longer to collect. Medicare and other payor claims relating to new clinics awaiting Medicare Rehab Agency status approval initially may not be submitted for six months or more. When all reasonable internal collection efforts have been exhausted, accounts are written off prior to sending them to outside collection firms. With managed care, commercial health plans and self-pay payor type receivables, the write-off generally occurs after the account receivable has been outstanding for at least 120 days.

We generally enter into various notes payable as a means of financing our acquisitions. Our present outstanding notes payable relate to certain of the acquisitions of businesses that occurred in 2014 and 2013. For those acquisitions, we entered into several notes payables aggregating $1.7 million. The notes are payable in equal annual installments of principal over two years plus any accrued and unpaid interest. Interest accrues at 3.25% per annum, subject to adjustment. In addition, we assumed leases with remaining terms of 1 month to 6 years for the operating facilities. At September 30, 2014, the balance on these notes payable was $1.3 million.

In conjunction with the above mentioned acquisitions, in the event that a limited minority partner’s employment ceases at any time after three years from the acquisition date, we have agreed to repurchase that individual’s non-controlling interest at a predetermined multiple of earnings before interest and taxes.

As of September 30, 2014, we have accrued $1.6 million related to credit balances and overpayments due to patients and payors. This amount is expected to be paid during the twelve months ended September 30, 2015.

From September 2001 through December 31, 2008, our Board of Directors (“Board”) authorized us to purchase, in the open market or in privately negotiated transactions, up to 2,250,000 shares of our common stock. In March 2009, the Board authorized the repurchase of up to 10% or approximately 1,200,000 shares of our common stock (“March 2009 Authorization”). In connection with the March 2009 Authorization, we amended our bank credit agreement to permit share repurchases of up to $15,000,000. We are required to retire shares purchased under the March 2009 Authorization. Effective October 24, 2012, we amended the Credit Agreement to permit us to purchase, commencing on October 24, 2012 and at all times thereafter, up to $15,000,000 of our common stock subject to compliance with covenants.

There is no expiration date for the share repurchase program. As of September 30, 2014, there are currently an additional estimated 341,000 shares that may be purchased from time to time in the open market or private transactions depending on price, availability and our cash position. We did not purchase any shares of our common stock during the nine months ended September 30, 2014.

FACTORS AFFECTING FUTURE RESULTS

The risks related to our business and operations include:

  • Changes as a result of healthcare reform legislation, and implementation thereof, may affect our business.
  • We depend upon reimbursement by third-party payors including Medicare and Medicaid.
  • Changes in economic conditions in the United States may have a material adverse impact on our business and financial condition.
  • We depend upon the cultivation and maintenance of relationships with physicians in our markets.
  • We depend upon our ability to recruit and retain experienced physical and occupational therapists.
  • Our revenues may fluctuate seasonally due to weather.
  • Our operations are subject to extensive regulation.
  • We operate in a highly competitive industry.
  • We may incur closure costs and losses.
  • Future acquisitions may use significant resources, may be unsuccessful and could expose us to unforeseen liabilities.
  • Certain of our internal controls, particularly as they relate to billings and cash collections, are largely decentralized at our clinic locations.

See Risk Factors in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2013.

Forward-Looking Statements

We make statements in this report that are considered to be forward-looking within the meaning under Section 21E of the Securities Exchange Act of 1934, as amended. These statements contain forward-looking information relating to our financial condition, results of operations, plans, objectives, future performance and business. These statements (often using words such as “believes”, “expects”, “intends”, “plans”, “appear”, “should” and similar words) involve risks and uncertainties that could cause actual results to differ materially from those we project. Included among such statements are those relating to opening new clinics, availability of personnel and the reimbursement environment. The forward-looking statements are based on our current views and assumptions and actual results could differ materially from those anticipated in such forward-looking statements as a result of certain risks, uncertainties, and factors, which include, but are not limited to:

  • changes as the result of government enacted national healthcare reform;
  • changes in Medicare guidelines and reimbursement or failure of our clinics to maintain their Medicare certification status;
  • business and regulatory conditions including federal and state regulations;
  • changes in reimbursement rates or payment methods from third party payors including government agencies and deductibles and co-pays owed by patients;
  • revenue and earnings expectations;
  • general economic conditions;
  • availability and cost of qualified physical and occupational therapists;
  • personnel productivity;
  • competitive, economic or reimbursement conditions in our markets which may require us to reorganize or close certain clinics and thereby incur losses and/or closure costs including the possible write-down or write-off of goodwill and other intangible assets;
  • acquisitions, purchase of non-controlling interests (minority interests) and the successful integration of the operations of the acquired businesses;
  • maintaining adequate internal controls;
  • availability, terms, and use of capital; and
  • weather and other seasonal factors.

Many factors are beyond our control. Given these uncertainties, you should not place undue reliance on our forward-looking statements. Please see our periodic reports filed with the Securities and Exchange Commission (the “SEC”) for more information on these factors. Our forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as required by law, we are under no obligation to update any forward-looking statement, regardless of the reason the statement is no longer accurate.

Market risk

As filed, 559 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We do not maintain any derivative instruments, interest rate swap arrangements, hedging contracts, futures contracts or the like. Our primary market risk exposure is the changes in interest rates obtainable on our Credit Agreement. The interest on our Credit Agreement is based on a variable rate. At September 30, 2014, $46.5 million was outstanding under our Credit Agreement. Based on the balance of the Credit Agreement at September 30, 2014, any change in the interest rate of 1% would yield a decrease or increase in annual interest expense of $465,000.

Controls and procedures

As filed, 1,386 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

(a) Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, the Company’s management completed an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures. Based on this evaluation, our principal executive officer and principal financial officer concluded (i) that our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure and (ii) that our disclosure controls and procedures are effective.

(b) Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2014-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2014-07-01 to 2014-09-30$77.7mus-gaap:SalesRevenueNet
Revenue9 months2014-01-01 to 2014-09-30$225.7mus-gaap:SalesRevenueNet
Gross profit3 months2014-07-01 to 2014-09-30$18.7mus-gaap:GrossProfit
Gross profit9 months2014-01-01 to 2014-09-30$57.2mus-gaap:GrossProfit
Operating income3 months2014-07-01 to 2014-09-30$11.3mus-gaap:OperatingIncomeLoss
Operating income9 months2014-01-01 to 2014-09-30$35.0mus-gaap:OperatingIncomeLoss
Interest expense3 months2014-07-01 to 2014-09-30$237.0kus-gaap:InterestExpense
Interest expense9 months2014-01-01 to 2014-09-30$822.0kus-gaap:InterestExpense
Income tax3 months2014-07-01 to 2014-09-30$3.6mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2014-01-01 to 2014-09-30$11.0mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2014-07-01 to 2014-09-30$5.2mus-gaap:NetIncomeLoss
Net income9 months2014-01-01 to 2014-09-30$15.9mus-gaap:NetIncomeLoss
Diluted EPS3 months2014-07-01 to 2014-09-30$0.43us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2014-01-01 to 2014-09-30$1.21us-gaap:EarningsPerShareDiluted
Basic EPS3 months2014-07-01 to 2014-09-30$0.43us-gaap:EarningsPerShareBasic
Basic EPS9 months2014-01-01 to 2014-09-30$1.21us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2014-07-01 to 2014-09-3012,247,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2014-01-01 to 2014-09-3012,208,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2014-01-01 to 2014-09-30$28.8mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2014-01-01 to 2014-09-30$3.9mus-gaap:PaymentsToAcquireProductiveAssets
Dividends paid9 months2014-01-01 to 2014-09-30$4.4mus-gaap:PaymentsOfDividendsCommonStock
Cash and equivalentsAt period end2014-09-30$15.8mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2014-09-30$56.6mus-gaap:AssetsCurrent
Total assetsAt period end2014-09-30$247.7mus-gaap:Assets
Current liabilitiesAt period end2014-09-30$21.8mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2014-09-30$77.2mus-gaap:Liabilities
Long-term debtAt period end2014-09-30$47.0mus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2014-09-30$850.0kus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2014-09-30$141.7mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001140361-14-040631. Last ingested by Listed: Nov 14, 2026, 13:45 ET. Listed shows no prices and gives no investment advice.